Advertisement
Drug Pipeline
Subscribe to Drug Pipeline
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Neurocrine Initiates Clinical Trial for Tourette Syndrome Therapy

October 3, 2014 2:58 pm | News | Comments

Neurocrine Biosciences, Inc. announced that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome. Read more...      

Halozyme Gets Orphan Drug Designation for Pancreatic Cancer Drug

October 3, 2014 2:49 pm | News | Comments

Halozyme Therapeutics, Inc. announced that the FDA has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Read more...                             

Record Number of Clinical Trials for Multiple Myeloma this Year

October 3, 2014 2:11 pm | News | Comments

The Multiple Myeloma Research Consortium (MMRC) announced that it has opened six new clinical trials in 2014, and is on track to open more multiple myeloma clinical trials during 2014 than any other year since the Consortium was founded in 2004. Read more...

Advertisement

Potential Therapy Spotted for Sudan Strain of Ebola

October 3, 2014 11:04 am | by Stephanie Guzowski, Editor | Articles | Comments

As the deadly Ebola outbreak in West Africa continues to grip headlines around the world, researchers move steadily forward with drug development. But as essential as it is to contain the current Ebola outbreak, researchers are looking at the bigger picture— and highlighting the need for therapy development to extend beyond the wake of the current epidemic. Read more...

Intarcia Announces Positive Results for Type 2 Diabetes Therapy

October 2, 2014 3:33 pm | News | Comments

Intarcia Therapeutics announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 . The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical trial that tested the efficacy and safety of ITCA 650 in patients with type 2 diabetes against placebo. Read more...

Ariad's Lung Cancer Drug Receives FDA Breakthrough Therapy Designation

October 2, 2014 3:21 pm | News | Comments

Ariad Pharmaceuticals, Inc. announced that its investigational cancer medicine, AP26113, has received Breakthrough Therapy designation by the FDA for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are resistant to crizotinib. Read more...

NKT Therapeutics’ Sickle Cell Disease Drug Receives FDA Fast Track

October 2, 2014 2:42 pm | News | Comments

NKT Therapeutics announced that FDA has granted Fast Track designation to NKTT120, the company’s lead therapeutic being developed for the treatment of sickle cell disease. Read more...

Experimental Ebola Vaccine Processed in Maryland

October 2, 2014 2:22 pm | News | Comments

The National Institute of Allergy and Infectious Diseases said an experimental Ebola vaccine is being processed at a facility in Frederick. The Frederick News-Post reported that the vaccine is a joint project between the federal agency and GlaxoSmithKline. Read more...

Advertisement

Amgen Announces Positive Data for Cholesterol-Lowering Medication

October 2, 2014 2:12 pm | News | Comments

Amgen announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in a statistically significant reduction in LDL-C compared to placebo in patients with different types of familial hypercholesterolemia (FH). Read more...

Takeda Announces Phase 3 Data for UC, Crohn's Drug

October 2, 2014 10:29 am | News | Comments

Takeda announced that new data from GEMINI LTS, a Phase 3, ongoing, open-label extension study of Entyvio (vedolizumab) for the treatment of adults with moderately to severely active UC and CD will be presented as oral presentations during the 21st United European Gastroenterology Week in Vienna, Austria. Read more...

Drugmaker Submits Harder-to-Abuse Zohydro to FDA

October 2, 2014 9:33 am | by Matthew Perrone, AP Health Writer | News | Comments

The maker of the much-debated painkiller Zohydro is seeking approval of a harder-to-abuse version of the drug which, if approved, could replace the currently marketed version of the pill by next spring. Read more...          

Nine-Valent HPV Vaccine May Prevent Nearly 90% of Cervical Cancers

October 1, 2014 3:59 pm | News | Comments

Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to new research. Read more...

Daiichi Sankyo Submits Cravit sNDA in Japan

October 1, 2014 12:57 pm | News | Comments

Daiichi Sankyo Co. Ltd. announced that it and its domestic generic subsidiary, Daiichi Sankyo Espha Co. Ltd., have submitted a supplemental New Drug Application (sNDA) in Japan for the synthetic broad-spectrum oral antibacterial agent Cravit Tablets. Read more...

Advertisement

Targeted Treatment Could Halt Womb Cancer Growth

October 1, 2014 10:06 am | News | Comments

A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer. Read more...

Early Antibiotic Use Linked to Childhood Obesity Risk

September 30, 2014 3:16 pm | News | Comments

The use of broad-spectrum antibiotics by children before the age of 24 months was associated with increased risk of obesity in early childhood. Read more...                         

Scientists Engineer Antibiotics in Race Against Drug Resistance

September 30, 2014 2:56 pm | News | Comments

We face an urgent global health problem because scientists are not developing new antibiotics as fast as bacteria are developing antibiotic resistance. But new research from UCLA has made important progress toward solving this problem. Read more...

Engineers Devise Technology for Rapidly Testing Drug-Delivery Vehicles

September 30, 2014 2:43 pm | News | Comments

Engineers have devised a way to rapidly test hundreds of different drug-delivery vehicles in living animals, making it easier to discover promising new ways to deliver a class of drugs called biologics, which includes antibodies, peptides, RNA, and DNA, to human patients. Read more...

Testing Cancer Drugs' Benefit for Individual Patients

September 30, 2014 2:28 pm | News | Comments

An official at a life sciences startup based on a Purdue University innovation says his company may help oncologists see faster than ever which drug therapies will benefit cancer patients and to what extent. Read more...         

Viagra Ads Target Women for First Time

September 30, 2014 1:52 pm | by Linda Johnson, AP Business Writer | News | Comments

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women. Read more...

Sanofi, Regeneron Announce Positive Dupilumab Results

September 30, 2014 11:00 am | News | Comments

Regeneron Pharmaceuticals and Sanofi announced that a Phase 2a study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. Read more...

Pfizer, Kyowa Hakko Kirin Partner on Immuno-Oncology Combo Study

September 30, 2014 10:49 am | News | Comments

Pfizer Inc. and Kyowa Hakko Kirin announced that they've entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab. Read more...         

NIH Awards Seven New Vaccine Adjuvant Discovery Contracts

September 30, 2014 10:37 am | News | Comments

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability. Read more...

Takeda, Seattle Genetics Receive Positive Data from Lymphoma Trial

September 30, 2014 10:02 am | News | Comments

Seattle Genetics and Takeda Pharmaceutical Co. Ltd. announced that patients with Hodgkin lymphoma (HL) who received Adcetris (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplantation (ASCT) lived significantly longer without disease progression compared to patients who received placebo. Read more...

Array's Melanoma Drug Promising in Phase 2

September 29, 2014 3:46 pm | News | Comments

Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain. Invented by Array BioPharma Inc. and licensed to Novartis in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2. Read more...

Tonix Fibromyalgia Pain Drug Misses Endpoint in Phase 2b

September 29, 2014 3:28 pm | News | Comments

Tonix Pharmaceuticals announced results of the Phase 2b BESTFIT study of TNX-102 SL as a chronic bedtime treatment for fibromyalgia. The study did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading